Urology
Volume 72, Issue 5 , Pages 1125-1129 , November 2008

Does Timing of Androgen Deprivation Influence Radiation-Induced Toxicity? A Secondary Analysis of Radiation Therapy Oncology Group Protocol 9413

This study was presented as a poster at the American Society for Therapeutic Radiology and Oncology Annual Meeting, Philadelphia, November 2006.

  • Daniel Taussky

      Affiliations

    • Department of Radiation Oncology, Montreal University, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Daniel Taussky, M.D., Department of Radiation Oncology, Centre Hospitalier Universitaire de Montréal Hôpital Notre-Dame, 1560 Sherbrooke Street East, Montreal, H2L 4M1 QC Canada
    • ,
  • Kyounghwa Bae

      Affiliations

    • Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, Pennsylvania
    • ,
  • Jean-Paul Bahary

      Affiliations

    • Department of Radiation Oncology, Montreal University, Montreal, Quebec, Canada
    • ,
  • Mack Roach III

      Affiliations

    • Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, California
    • ,
  • Colleen A. Lawton

      Affiliations

    • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • William U. Shipley

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Howard M. Sandler

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan

Received 3 August 2007 ,Accepted 13 November 2007.

References 

  1. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  2. Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1053–1061
  3. Sanguineti G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer. 2002;86:1843–1847
  4. Liu M, Pickles T, Agranovich A, et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2004;58:59–67
  5. Wachter S, Gerstner N, Goldner G, et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol. 2004;59:65–70
  6. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol. 2002;64:1–12
  7. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:397–405
  8. Palma D, Pickles T, Tyldesley S. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int. 2007;100:315–319
  9. Teloken C, Da Ros CT, Caraver F, et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005;174:2178–2180
  10. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425
  11. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997;49(3A suppl):38–45
  12. Hanks GE, Pajak TF, Porter A, et al. Radiation Therapy Oncology Group: phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  13. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005;23:800–807
  14. Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys. 2003;57:614–620
  15. Williams MB, Hernandez J, Thompson I. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol. 2005;173:1067–1071
  16. Nejat RJ, Rashid HH, Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000;164:1891–1894
  17. Padula GD, Zelefsky MJ, Venkatraman ES, et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:439–443
  18. Wang C, Catlin DH, Demers LM, et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534–543
  19. Matsumoto AM, Bremner WJ. Serum testosterone assays—accuracy matters. J Clin Endocrinol Metab. 2004;89:520–524
  20. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol. 2000;18:52–74
  21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509

 This study supported by RTOG U10, CA21661, CCOP U10 CA37422, and Stat U10 CA32115 grants from the National Cancer Institute.

 M. Roach is a study investigator funded by GlaxoSmithKline; is a paid consultant to Astra-Zeneca; and is a member of the speaker's bureau for TAP Pharmaceuticals and Siemens.

PII: S0090-4295(07)02448-X

doi: 10.1016/j.urology.2007.11.067

Urology
Volume 72, Issue 5 , Pages 1125-1129 , November 2008

Article Tools